文献速递乳腺癌

HER2DX与早期HER2阳性乳腺癌生存结局:个体患者水平Meta分析

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
PubMed 文献 · Lancet Oncol · 2025-07-14

该个体患者水平Meta分析纳入11项研究、2518例早期HER2阳性乳腺癌患者,评估HER2DX风险评分与生存结局的关联。中位随访6.1年,多变量分析显示HER2DX连续评分与无事件生存独立相关(每增加10个单位的分层HR 1.25,95%CI 1.14-1.38;p<0.0001)。低危组6年无事件生存率为93.6%,高危组为82.9%,绝对差异10.7%(分层HR 2.72,95%CI 1.97-3.76;p<0.0001)。

要点

  • HER2DX连续评分每增加10个单位,无事件生存风险分层HR为1.25(95%CI 1.14-1.38;p<0.0001)。
  • 低危组6年无事件生存率93.6% vs 高危组82.9%,绝对差异10.7%(分层HR 2.72,95%CI 1.97-3.76)。
  • 该关联在肿瘤分期、淋巴结分期、病理完全缓解或激素受体状态各亚组中一致。

核心结论

  • HER2DX在早期HER2阳性乳腺癌中提供有临床意义的预后分层,超越标准临床病理变量和病理缓解。

研究设计与样本

  • 系统综述与个体患者水平Meta分析,纳入1-3期HER2阳性乳腺癌研究,要求患者数>50例、接受抗HER2治疗且有生存结局和HER2DX检测。
  • 2024年12月15日在PubMed进行系统文献检索,并补充机构数据库审查;共11项研究(APT、ATEMPT、CALGB40601、DAPHNe、GOM-HGUGM-2018-05、NEOHER、SOLTI-PAMELA、PHERGain、HUAC、SCAN-B和DFCI-14-409)纳入分析。
  • 共识别3244例患者,2518例(有HER2DX临床数据和生存结局)纳入分析;中位随访6.1年(95%CI 6.0-6.3)。

主要发现

  • 2518例中,1期891例(35.4%)、2期1133例(45.0%)、3期494例(19.6%);激素受体阳性1660例(65.9%);HER2DX高危1259例(50.0%)。
  • 多变量分析中,HER2DX作为连续变量与无事件生存独立相关(每增加10个单位的分层HR 1.25,95%CI 1.14-1.38;p<0.0001)。
  • HER2DX低危组6年无事件生存率为93.6%(95%CI 92.0-95.2),高危组为82.9%(80.0-85.5),绝对差异10.7%(分层HR 2.72,95%CI 1.97-3.76;p<0.0001)。
  • 该关联在肿瘤分期、淋巴结分期、病理完全缓解或激素受体状态各亚组中一致。

关键数值与推荐

  • HER2DX风险评分采用预设界值分为低危与高危组。
  • 主要终点为无事件生存,采用Kaplan-Meier法估计,并用分层Cox模型估计分层HR。

临床怎么用

  • 作者认为这些结果支持使用HER2DX来调整治疗强度并指导临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2-positive breast cancer accounts for 15-20% of all breast cancers and is characterised by HER2 (also known as ERBB2) amplification. Although HER2-targeted therapies have markedly improved outcomes, current clinical-pathological variables and pathological complete response after neoadjuvant therapy are insufficient to fully capture biological heterogeneity and guide personalised treatment. HER2DX is a genomic test that integrates tumour biology and clinical data to stratify risk. Here, we conducted an individual patient-level meta-analysis to evaluate the association between the HER2DX risk score and survival outcomes in early-stage HER2-positive breast cancer. METHODS: We conducted a systematic review and individual patient-level meta-analysis using data from studies of stage 1-3 HER2-positive breast cancer, incorporating HER2DX risk scores, clinical information, and survival outcomes. A systematic literature search was conducted in PubMed on Dec 15, 2024, and complemented by a review of in-house databases to identify eligible studies with HER2DX testing and patient-level data. Eligible studies were required to include more than 50 patients with HER2-positive early breast cancer treated with anti-HER2 therapy, with available survival outcomes, and HER2DX testing performed. Individual-level data were requested from study investigators or accessed through public repositories. HER2DX risk score was evaluated as continuous score and as a risk group using pre-established cutoffs (low vs high). The primary endpoint of the study was event-free survival, estimated using the Kaplan-Meier method. Univariable and multivariable stratified Cox models were used to estimate stratified hazard ratios (HRs). The study was registered in PROSPERO (CRD42025634137). FINDINGS: 11 studies met the inclusion criteria (APT, ATEMPT, CALGB40601, DAPHNe, GOM-HGUGM-2018-05, NEOHER, SOLTI-PAMELA, PHERGain, HUAC, SCAN-B, and DFCI-14-409) and were selected for the meta-analysis. Of 3244 patients identified across the selected studies, 2518 were included in the analysis (those with available HER2DX clinical data and survival outcomes). The median follow-up was 6·1 years (95% CI 6·0-6·3). Of 2518 patients, 891 (35·4%) had stage 1 disease, 1133 (45·0%) stage 2 disease, and 494 (19·6%) stage 3 disease. Hormone receptor-positive disease was present in 1660 (65·9%) of 2518 patients and 1259 (50·0%) of 2518 patients had a high HER2DX risk score. In the multivariable analysis, HER2DX as a continuous variable was independently associated with event-free survival (stratified HR per 10-unit increment 1·25, 95% CI 1·14-1·38; p<0·0001). Patients classified as HER2DX low risk had a 6-year event-free survival rate of 93·6% (95% CI 92·0-95·2), compared with 82·9% (80·0-85·5) for the HER2DX high-risk group, representing a 10·7% absolute difference (stratified HR 2·72, 95% CI 1·97-3·76; p<0·0001). This association was consistent across subgroups, regardless of tumour stage, nodal stage, pathological complete response, or hormone receptor status. INTERPRETATION: HER2DX provides clinically meaningful prognostic stratification in early-stage HER2-positive breast cancer, beyond standard clinical-pathological variables and pathological response. These results support its use in tailoring treatment intensity and guiding clinical decision making. FUNDING: Reveal Genomics.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Villacampa G, Pascual T, Tarantino P, et al. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 2025. PMID: 40675165. doi:10.1016/S1470-2045(25)00276-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。